Prana gets OK for Alzheimer's drug trial

11/23/2011 | Wall Street Journal, The · MarketWatch

Prana Biotechnology said it got the OK from Australia's Austin Health Research Ethics Committee to move forward with a long-term Phase II trial of PBT2, its experimental drug for mild Alzheimer's disease. Researchers will use PiB-PET imaging to measure the drug's effect on amyloid deposits in patients' brains and F-FDG PET to determine effects on increasing brain activity.

View Full Article in:

Wall Street Journal, The · MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC